Hepatitis B and hepatocellular carcinoma - PubMed (original) (raw)

Hepatitis B and hepatocellular carcinoma

Adrian M Di Bisceglie. Hepatology. 2009 May.

Abstract

Chronic infection with the hepatitis B virus has been linked epidemiologically to the development of hepatocellular carcinoma for more than 30 years. Although the mechanisms by which chronic hepatitis B viral infection results in hepatocellular carcinoma are unclear, there is good evidence that the virus itself exerts a direct hepatocarcinogenic effect, and this has implications for prevention. First, programs of universal infant vaccination have been shown to be effective in reducing the rate of hepatocellular carcinoma among children. This benefit should be translated into adulthood among vaccine recipients. Second, it has been suggested that antiviral therapy against hepatitis B may reduce the risk of hepatocellular carcinoma. Antiviral therapy against hepatitis B is effective in causing prolonged lowering of serum levels of hepatitis B virus DNA. There are emerging data showing that prolonged antiviral therapy may reduce the risk of hepatocellular carcinoma among certain patients with chronic hepatitis B.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest: Dr Di Bisceglie has served as a consultant for Roche, Schering Plough, Gilead Sciences, Idenix, Novartis, Bristol-Myers-Squibb, Abbott and Pharmasset and has received research support from Roche, Gilead Sciences, Idenix and Pharmasset.

Figures

Figure 1. Etiology of HCC in the United States. Survey of 691 patients with HCC from 13 referral centers (8)

References

1. Sherlock S, Fox R, Niazi S, Scheuer P. Chronic liver disease and primary liver-cell cancer with hepatitis-associated (Australia) antigen in serum. Lancet. 1970;i:1243–1247. - PubMed
1. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22,707 men in Taiwan. Lancet. 1981;ii:1129–1133. - PubMed
1. Parkin D, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. International Journal of Cancer. 2001;94:153–156. - PubMed
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun M. Cancer Statistics, 2008. CA. A cancer journal for clinicians. 2008;58:71–96. - PubMed
1. Evans A, Chen GH, Ross E, Shen FM, Lin WY, London W. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality. risk factors, and gender differences. Cancer Epidemiology, Biomarkers & Prevention. 2002;11:369–376. - PubMed

Hepatitis B and hepatocellular carcinoma - PubMed (original) (raw)